JPMorgan raised the firm’s price target on PTC Therapeutics (PTCT) to $80 from $68 and keeps an Overweight rating on the shares following the Q3 report. The firm says PTC’s momentum in October “continued to look very favorable and sustained.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $93 from $73 at Wells Fargo
- PTC Therapeutics price target raised to $68 from $46 at Barclays
- PTC Therapeutics price target raised to $75 from $50 at Citi
- PTC Therapeutics: Strong Market Position and Growth Potential Drive Buy Rating
- PTC Therapeutics: Balancing Sephience Success with DMD Challenges and Strategic Shifts